- Home
- QNCX
as 07-26-2024 4:00pm EST
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 32.9M | IPO Year: | 2019 |
| Target Price: | N/A | AVG Volume (30 days): | 57.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.63 - $1.43 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Quince Therapeutics Inc. (QNCX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lamond David | QNCX | Director | Dec 12 '23 | Buy | $1.00 | 300 | $300.00 | 2,279,964 | SEC Form 4 |
| Lamond David | QNCX | Director | Dec 12 '23 | Buy | $1.02 | 22,327 | $22,773.54 | 2,302,291 | SEC Form 4 |
| Lamond David | QNCX | Director | Dec 12 '23 | Buy | $1.00 | 22,627 | $22,627.00 | 2,324,918 | SEC Form 4 |
| Lamond David | QNCX | Director | Dec 12 '23 | Buy | $1.04 | 22,627 | $23,532.08 | 2,347,545 | SEC Form 4 |
| Lamond David | QNCX | Director | Dec 5 '23 | Buy | $1.01 | 19,123 | $19,314.23 | 2,241,418 | SEC Form 4 |
| Lamond David | QNCX | Director | Dec 5 '23 | Buy | $1.02 | 19,123 | $19,505.46 | 2,260,541 | SEC Form 4 |
| Lamond David | QNCX | Director | Dec 5 '23 | Buy | $1.01 | 19,123 | $19,314.23 | 2,279,664 | SEC Form 4 |
| Lamond David | QNCX | Director | Nov 29 '23 | Buy | $0.98 | 14,378 | $14,090.44 | 2,193,539 | SEC Form 4 |
| Lamond David | QNCX | Director | Nov 29 '23 | Buy | $0.90 | 14,378 | $12,940.20 | 2,207,917 | SEC Form 4 |
| Lamond David | QNCX | Director | Nov 29 '23 | Buy | $0.94 | 14,378 | $13,515.32 | 2,222,295 | SEC Form 4 |
Latest Quince Therapeutics Inc. News
QNCX Breaking Stock News: Dive into QNCX Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
a month ago
Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial
MT Newswires
a month ago
Quince Therapeutics Doses First Patient in Phase 3 Trial of EryDex to Treat Ataxia-Telangiectasia
Business Wire
a month ago
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia
Business Wire
2 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
GlobeNewswire
2 months ago
Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
GlobeNewswire
2 months ago
Share buy-back programme - week 23
Simply Wall St.
2 months ago
Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
Reuters
2 months ago
Japan's service sector mood hits nearly 2-year low in May
Compare QNCX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QNCX Quince Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.